Inovio Pharmaceuticals (INO) Price & Analysis

Compare

5,922 Followers

INO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.30 - $6.03

Previous CloseN/A

Volume1.36M

Average Volume (3M)2.14M

Market Cap

$131.79M

Enterprise Value$42.13M

Total Cash (Recent Filing)$47.55M

Total Debt (Recent Filing)$10.66M

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Nov 11, 2025

EPS Estimate

-0.42

Last Dividend Ex-Date

Sep 28, 2017

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding53,142,662

10 Day Avg. Volume1,039,326

30 Day Avg. Volume2,137,037

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.32

Enterprise Value/Revenue231.04

Enterprise Value/Gross Profit-20.05

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$6.96

Price Target Upside197.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyINO-3107 provided significant clinical benefit to RRP patients, as measured by reduction in surgery, which continued to improve in years two and three following initial treatment.

Regulatory ProgressThe company is on track to submit the Biologics License Application (BLA) for INO-3107, with the goal of having FDA acceptance of the submission by the end of 2025.

Bears Say

Capital RequirementsThe company may need to raise additional capital within the next 12 months.

Regulatory Approval RisksINO-3107 may not gain regulatory approval in RRP or meet sales forecasts.

Inovio Pharmaceuticals News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: YIELDMAX COIN OPTION INCOME...

16d ago

BNC

Inovio Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

Inovio Pharmaceuticals (($INO)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

INO

Inovio to begin rolling submission of BLA for INO-3107

Inovio (INO) announced that the FDA has notified the company that it agrees with its rolling submission timeline...

1M ago

INO

Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals, with a price target of...

2M ago

INO

Inovio Pharmaceuticals Reports Q2 2025 Financial Progress

Inovio Pharmaceuticals ( ($INO) ) has released its Q2 earnings. Here is a breakdown of the information Inovio...

2M ago

INO

Inovio reports Q2 EPS (61c), consensus (62c)

“With device DV testing complete, we remain on track to submit our BLA for INO-3107 in the second...

2M ago

INO

Options Volatility and Implied Earnings Moves Today, August 12, 2025

Today, several major companies are expected to report earnings: Inovio Pharmaceuticals (INO), Altimmune (ALT), Sea (SE), Luminar Technologies...

2M ago

ALT

Inovio announces peer-reviewed data from INO-3107 study

Inovio (INO) announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of...

2M ago

INO

Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025

This week, several major companies will be reporting earnings. Among them are Plug Power (PLUG), Cisco Systems (CSCO),...

2M ago

INO Earnings this Week: How Will it Perform?

Inovio Pharmaceuticals (INO) is scheduled to report 2nd quarter earnings on 08/06/2025. Regarding Q2 estimates, Wall Street analysts...

2M ago

INO

Inovio, Sunrun, Super Micro, Microsoft, Caterpillar: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($INO) ), ( ($RUN) ), ( ($SMCI) ), ( ($MSFT)...

3M ago

CAT

INO

Inovio’s Urothelial Carcinoma Study Update: Potential Market Impacts

Inovio Pharmaceuticals (($INO)) announced an update on their ongoing clinical study. Inovio Pharmaceuticals recently updated their clinical study...

3M ago

INO

Inovio initiated with an Overweight at Piper Sandler

Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio (INO) with an Overweight rating and $5 price target...

3M ago

INO

Inovio Pharmaceuticals Announces Public Offering Agreement

Inovio Pharmaceuticals ( ($INO) ) has shared an announcement. On July 2, 2025, INOVIO Pharmaceuticals entered into an...

3M ago

INO

INO FAQ

What was Inovio Pharmaceuticals’s price range in the past 12 months?

Inovio Pharmaceuticals lowest stock price was $1.30 and its highest was $6.03 in the past 12 months.

What is Inovio Pharmaceuticals’s market cap?

Inovio Pharmaceuticals’s market cap is $131.79M.

When is Inovio Pharmaceuticals’s upcoming earnings report date?

Inovio Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 41 days.

How were Inovio Pharmaceuticals’s earnings last quarter?

Inovio Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.61 earnings per share for the quarter, the consensus estimate of -$0.61 by $0.

Is Inovio Pharmaceuticals overvalued?

According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here

What is Inovio Pharmaceuticals’s EPS estimate?

Inovio Pharmaceuticals’s EPS estimate is -0.42.

How many shares outstanding does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals has 53,142,662 shares outstanding.

What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?

Inovio Pharmaceuticals reported an EPS of -$0.61 in its last earnings report, expectations of -$0.61. Following the earnings report the stock price went up 14.094%.

Which hedge fund is a major shareholder of Inovio Pharmaceuticals?

Currently, no hedge funds are holding shares in INO

Inovio Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-140.12%

Trailing 12-Months

Asset Growth

-49.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inovio Pharmaceuticals

Inovio Pharmaceuticals (INO) is a biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company specializes in its proprietary platform technology that delivers therapeutic DNA plasmids into the body, harnessing the immune system to generate a targeted response. Inovio's core products include its investigational therapies for various cancers and its work on vaccines against infectious diseases, including COVID-19.

Inovio Pharmaceuticals (INO) Earnings & Revenues

Historic Earnings Reports

INO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress with the BLA submission for INO-3107, successful FDA inspections, and advancements in DNA medicine technology, suggesting a promising outlook. However, concerns over decreased cash reserves and potential competition were noted.View all INO earnings summaries

INO Stock 12 Month Forecast

Average Price Target

$6.96

▲(197.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,3.3723076923076922,4.174615384615384,4.976923076923077,5.779230769230769,6.581538461538461,7.383846153846154,8.186153846153847,8.988461538461538,9.79076923076923,10.593076923076923,11.395384615384616,12.197692307692307,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,2.9076923076923076,3.2453846153846153,3.583076923076923,3.920769230769231,4.258461538461539,4.596153846153847,4.933846153846154,5.271538461538462,5.60923076923077,5.946923076923078,6.284615384615385,6.622307692307693,{"y":6.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,2.5107692307692306,2.4515384615384614,2.3923076923076922,2.333076923076923,2.273846153846154,2.2146153846153847,2.1553846153846155,2.0961538461538463,2.036923076923077,1.9776923076923079,1.9184615384615387,1.8592307692307692,{"y":1.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.02,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >